Argentina Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Argentina recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Argentina recombinant protein therapeutics cdmo market highlights
- The Argentina recombinant protein therapeutics cdmo market generated a revenue of USD 89.4 million in 2023 and is expected to reach USD 214.6 million by 2030.
- The Argentina market is expected to grow at a CAGR of 13.3% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 89.4 million |
| Market revenue in 2030 | USD 214.6 million |
| Growth rate | 13.3% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Argentina accounted for 0.4% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 811.0 million by 2030.
Interferons was the largest segment with a revenue share of 21.48% in 2023. Horizon Databook has segmented the Argentina recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing demand for generic drugs in the growing biopharmaceutical industry is expected to propel the need for new drug development, which is expected to drive market growth over the forecast period. The diversified population and the availability of experienced health professionals encourage pharmaceutical companies to conduct clinical trials in Argentina.
According to Clinical Trials.gov., around 404 clinical trials were registered from 2022 to 2023 in Argentina. Moreover, the pharmaceutical industry is growing at a moderate pace in the country, mainly due to increase in R&D activities. In addition, the national companies are responsible for 50% of production sales in the country. This provides a competitive side to the pharmaceutical market. Furthermore, the clinical trials are cost-effective in Argentina, and recommendations of the WHO’s GMPs and control standards have been implemented, aiding market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Argentina recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Argentina Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
